Immune Design Corp (IMDZ)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Immune Design Corp (IMDZ)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH139803D
  • |
  • Pages: 48
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Immune Design Corp (Immune Design) is a clinical-stage immunotherapy company that discovers and develops in vivo immunotherapy treatments to target cancer and other chronic diseases. The company develops its product candidates through its ZVex and GLAAS discovery platforms. Its product candidates are intended for the treatment of NY-ESO-1 tumor antigen, merkel cell carcinoma, non-hodgkin lymphoma, and others. It has collaboration with various pharmaceutical companies, to develop its product candidates through its GLAAS platform for the treatment of infectious disease, allergy and autoimmune diseases. The company also operates in San Francisco, California. Immune Design is headquartered in Seattle, Washington, the US.

Immune Design Corp (IMDZ)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Immune Design Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Immune Design Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Immune Design Corp, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Immune Design Raises US$32.5 Million In Series C Financing 12

Immune Design Raises US$34 Million In Series B Financing 13

Immune Design Raises USD0.02 Million in Venture Financing 14

Partnerships 15

Immune Design Enters into Agreement with Gritstone Oncology 15

Immune Design Enters into Clinical Trial Collaboration with Genentech 16

Immune Design Enters into Clinical Collaboration Agreement with Merck 17

Immune Design Enters into Co-Development Agreement with Sanofi Pasteur 17

Immune Design Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute For Cancer Research 18

Licensing Agreements 20

Immune Design Licensing Agreement with Oxford BioMedica 20

Sanofi Enters into Licensing Agreement with Immune Design 21

Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 22

Immune Design Enters into Licensing Agreement with UNC Chapel Hill 23

Equity Offering 24

Immune Design Prices Public Offering of Shares for USD30 Million 24

Immune Design to Raise USD250 million in Public offering of Shares 25

Immune Design Completes Underwriters Partial Exercise of Over-Allotment of Public Offering of Shares 26

Immune Design Raises USD60 Million in IPO 27

Immune Design Corp-Key Competitors 30

Key Employees 31

Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

Mar 07, 2017: Immune Design Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 33

Nov 09, 2016: Immune Design Reports Third Quarter 2016 Financial Results and Provides Corporate Update 35

Aug 09, 2016: Immune Design Reports Second Quarter 2016 Financial Results and Provides Corporate Update 37

May 10, 2016: Immune Design Reports First Quarter 2016 Financial Results and Provides Corporate Update 39

Mar 10, 2016: Immune Design Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update 41

Corporate Communications 43

Oct 04, 2016: Immune Design Appoints Sergey Yurasov, M.D., Ph.D. as Senior Vice President of Clinical Development and Chief Medical Officer 43

Jun 16, 2016: Immune Design Appoints Susan L. Kelley, M.D. to Board of Directors 44

Product News 45

Dec 05, 2016: Immune Design announces updates on Intratumoral immunization approaches 45

Product Approvals 46

Jan 08, 2016: Immune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305 46

Clinical Trials 47

Feb 09, 2016: Immune Design Announces Positive Topline Data From Phase 1 Clinical Trial of CMB305 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48

List of Figures

Immune Design Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Immune Design Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Immune Design Corp, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Immune Design Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Immune Design Corp, Deals By Therapy Area, 2011 to YTD 2017 9

Immune Design Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Immune Design Raises US$32.5 Million In Series C Financing 12

Immune Design Raises US$34 Million In Series B Financing 13

Immune Design Raises USD0.02 Million in Venture Financing 14

Immune Design Enters into Agreement with Gritstone Oncology 15

Immune Design Enters into Clinical Trial Collaboration with Genentech 16

Immune Design Enters into Clinical Collaboration Agreement with Merck 17

Immune Design Enters into Co-Development Agreement with Sanofi Pasteur 17

Immune Design Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute For Cancer Research 18

Immune Design Licensing Agreement with Oxford BioMedica 20

Sanofi Enters into Licensing Agreement with Immune Design 21

Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 22

Immune Design Enters into Licensing Agreement with UNC Chapel Hill 23

Immune Design Prices Public Offering of Shares for USD30 Million 24

Immune Design to Raise USD250 million in Public offering of Shares 25

Immune Design Completes Underwriters Partial Exercise of Over-Allotment of Public Offering of Shares 26

Immune Design Raises USD60 Million in IPO 27

Immune Design Corp, Key Competitors 30

Immune Design Corp, Key Employees 31

Immune Design Corp, Other Locations 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Immune Design Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16143
Site License
USD 500 INR 32285
Corporate User License
USD 750 INR 48428

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com